Cytek在Beckman Coulter专利诉讼中被判赔约5611万美元且拟上诉

----- 0001193125-26-361705-index-headers.html -----
<SEC-DOCUMENT>0001193125-26-361705-index.html : 20260824
<SEC-HEADER>0001193125-26-361705.hdr.sgml : 20260824
<ACCEPTANCE-DATETIME>20260824060123
ACCESSION NUMBER: 0001193125-26-361705
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 12
CONFORMED PERIOD OF REPORT: 20260821
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytek Biosciences, Inc.
CENTRAL INDEX KEY: 0001831915
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
EIN: 472547526
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40632
FILM NUMBER: 261306261
BUSINESS ADDRESS:
STREET 1: 47215 LAKEVIEW BOULEVARD
CITY: FREMONT
STATE: CA
ZIP: 94538
BUSINESS PHONE: (877) 922-9835
MAIL ADDRESS:
STREET 1: 47215 LAKEVIEW BOULEVARD
CITY: FREMONT
STATE: CA
ZIP: 94538
FORMER COMPANY:
FORMER CONFORMED NAME: Cytek BioSciences, Inc.
DATE OF NAME CHANGE: 20201110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d137695d8k.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: d137695d8k.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d137695dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: d137695dex991.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ctkb-20260821.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
Document 3 - file: ctkb-20260821.xsd
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ctkb-20260821_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
Document 4 - file: ctkb-20260821_lab.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ctkb-20260821_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
Document 5 - file: ctkb-20260821_pre.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 7 - file: R1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 8 - file: report.css
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 9 - file: Show.js
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 11 - file: FilingSummary.html
Document 11 - RAW XML: FilingSummary.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 13 - file: MetaLinks.json
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-26-361705-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 14 - file: 0001193125-26-361705-xbrl.zip
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>d137695d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 15 - file: d137695d8k_htm.html
Document 15 - RAW XML: d137695d8k_htm.xml
</DOCUMENT>
</SEC-DOCUMENT>

----- 0001193125-26-361705.txt -----
0001193125-26-361705.txt : 20260824
0001193125-26-361705.hdr.sgml : 20260824
20260824060123
ACCESSION NUMBER: 0001193125-26-361705
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 12
CONFORMED PERIOD OF REPORT: 20260821
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytek Biosciences, Inc.
CENTRAL INDEX KEY: 0001831915
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
EIN: 472547526
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40632
FILM NUMBER: 261306261
BUSINESS ADDRESS:
STREET 1: 47215 LAKEVIEW BOULEVARD
CITY: FREMONT
STATE: CA
ZIP: 94538
BUSINESS PHONE: (877) 922-9835
MAIL ADDRESS:
STREET 1: 47215 LAKEVIEW BOULEVARD
CITY: FREMONT
STATE: CA
ZIP: 94538
FORMER COMPANY:
FORMER CONFORMED NAME: Cytek BioSciences, Inc.
DATE OF NAME CHANGE: 20201110
8-K
1
d137695d8k.htm
8-K
8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 21, 2026
Cytek Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-40632
47-2547526
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
47215 Lakeview Boulevard
Fremont
,
California
94538
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
(877)
922-9835
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
CTKB
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On August 21, 2026, Cytek Biosciences, Inc. (the “Company”) announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information contained in this Item 7.01 of this Current Report on Form
8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing.
Item 8.01 Other Events.
On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company’s favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost profits and $36.11 million in royalties. The Company intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award. The Company may also pursue other available post-trial remedies, including potentially an appeal to the United States Court of Appeals for the Federal Circuit.
Forward-Looking Statements
This Current Report on Form
8-K
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include statements regarding the Company’s intention to pursue post-trial motions, appeals, or other proceedings related to the litigation. These statements are based on management’s current expectations and deal with future events and involve risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these statements. Factors that could cause actual results to differ materially include the outcome and impact of any post-trial motions, appeals, and further legal proceedings, including additional costs, injunctive relief, ongoing royalty obligations as determined by the court, and/or other risks discussed in the section titled “Risk Factors” set forth in the Company’s most recently filed Quarterly Report on Form
10-Q
filed with the SEC on August 5, 2026, and other filings the Company makes with the SEC from time to time.
Forward-looking
statements contained in this Current Report on Form
8-K
are made as of this date, and the Company undertakes no obligation to update any forward-looking statements, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Cytek Biosciences, Inc. dated August 21, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cytek Biosciences, Inc.
Date: August 24, 2026
By:
/s/ Wenbin Jiang
Wenbin Jiang, Ph.D.
President and Chief Executive Officer
EX-99.1
2
d137695dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge
Remaining Finding
FREMONT, Calif.,
August
21, 2026
(GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced
that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek’s favor on three of the four asserted patent claims,
finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of
$20 million in lost profits and $36 million in royalties. Cytek intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award.
The verdict does not require any changes to the Company’s current product offerings or operations, and Cytek’s spectral flow cytometry products
remain available to customers worldwide.
“We are pleased that the jury found in our favor on the substantial majority of claims in this case,
including findings of noninfringement and invalidity as to three of the four asserted claims,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “We fundamentally disagree with the single remaining finding and damages award and
intend to pursue all available post-trial remedies, including potentially an appeal to the United States Court of Appeals for the Federal Circuit. Cytek independently developed a fundamentally different approach to flow cytometry when we pioneered
Full Spectrum Profiling technology.”
Cytek will continue to invest in its proprietary and patented Full Spectrum Profiling
™
platform and remains committed to delivering innovative cell analysis solutions to researchers and clinicians worldwide.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq:
CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling
™
(FSP
®
) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to
achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora
™
, Northern Lights
™
, Cytek Aurora
™
CS, Cytek Aurora
™
Evo, and Cytek Borealis
™
systems; the Cytek Orion
™
reagent cocktail preparation system; the Enhanced Small
Particle
™
(ESP
™
) detection technology; the flow cytometers and imaging products under the Amnis
®
and Guava
®
brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers.
Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at
www.cytekbio.com
.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC
system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle,
ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC),
press releases, public conference calls and webcasts, Cytek uses its website
(www.cytekbio.com
),
LinkedIn page
and
X
account
as channels of distribution for information about the company, its products, planned financial
and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such
information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public
conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements
of historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,”
“plan,” “could,” “intend,” “believe,” “predict,” “potential,” or “continue” or the negatives of these terms or variations of them or similar terminology, but the
absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the Company’s expectations concerning the impact of the jury verdict and
damages award, and the outcome and impact of any post-trial motions, appeals, or other proceedings related to the litigation and their potential impact; the Company’s belief in the merits of its legal positions and grounds for appeal; the
potential impact of the verdict and damages award on the Company’s financial condition, results of operations, or product offerings; and the Company’s growth strategy and future financial performance. These statements are based on
management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual
results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to
predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include: the impact of the jury verdict and damages award, and the outcome and impact of
any post-trial motions, appeals, and further legal proceedings, including additional costs, injunctive relief, ongoing royalty obligations as determined by the court, and/or other potential liabilities; global geopolitical, economic and market
conditions; and other risks discussed in the section titled “Risk Factors” set forth in the Company’s most recently filed Quarterly Report on Form
10-Q
filed with the SEC on August 5,
2026, and other filings the Company makes with the SEC from time to time, which contain a discussion of important factors that may cause actual results to differ materially from those expressed or implied by the Company’s forward-looking
statements. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information
available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change
in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of
this press release.
Media Contact:
Stephanie Olsen
Lages & Associates
(949)
453-8080
stephanie@lages.com
Investor Contact:
Mark Meehan
Head of Investor Relations
Cytek Biosciences
mmeehan@cytekbio.com
EX-101.SCH
3
ctkb-20260821.xsd
XBRL TAXONOMY EXTENSION SCHEMA
100000 - Document - Document and Entity Information
link:calculationLink
link:presentationLink
link:definitionLink
EX-101.LAB
4
ctkb-20260821_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE
Cover [Abstract]
Cover [Abstract]
Amendment Flag
Amendment Flag
Entity Central Index Key
Entity Central Index Key
Document Type
Document Type
Document Period End Date
Document Period End Date
Entity Registrant Name
Entity Registrant Name
Entity Incorporation State Country Code
Entity Incorporation State Country Code
Entity File Number
Entity File Number
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, City or Town
Entity Address, State or Province
Entity Address, State or Province
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Written Communications
Written Communications
Soliciting Material
Soliciting Material
Pre Commencement Tender Offer
Pre Commencement Tender Offer
Pre Commencement Issuer Tender Offer
Pre Commencement Issuer Tender Offer
Security 12b Title
Security 12b Title
Trading Symbol
Trading Symbol
Security Exchange Name
Security Exchange Name
Entity Emerging Growth Company
Entity Emerging Growth Company
EX-101.PRE
5
ctkb-20260821_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
XML
7
R1.htm
IDEA: XBRL DOCUMENT
Document and Entity Information
Aug. 21, 2026
Cover [Abstract]
Amendment Flag
false
Entity Central Index Key
0001831915
Document Type
8-K
Document Period End Date
Aug. 21, 2026
Entity Registrant Name
Cytek Biosciences, Inc.
Entity Incorporation State Country Code
DE
Entity File Number
001-40632
Entity Tax Identification Number
47-2547526
Entity Address, Address Line One
47215 Lakeview Boulevard
Entity Address, City or Town
Fremont
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
94538
City Area Code
(877)
Local Phone Number
922-9835
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common Stock, par value $0.001 per share
Trading Symbol
CTKB
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
XML
8
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
9
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
11
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
22
1
false
0
0
false
0
false
false
R1.htm
100000 - Document - Document and Entity Information
Sheet
http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation
Document and Entity Information
Cover
1
false
false
All Reports
Book
All Reports
ctkb-20260821.xsd
ctkb-20260821_lab.xml
ctkb-20260821_pre.xml
d137695d8k.htm
http://xbrl.sec.gov/dei/2025
true
false
JSON
13
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"d137695d8k.htm": {
"nsprefix": "ctkb",
"nsuri": "http://cytekbio.com/20260821",
"dts": {
"schema": {
"local": [
"ctkb-20260821.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
"https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
"https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
"https://xbrl.sec.gov/country/2025/country-2025.xsd",
"https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
"https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
"https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
]
},
"labelLink": {
"local": [
"ctkb-20260821_lab.xml"
]
},
"presentationLink": {
"local": [
"ctkb-20260821_pre.xml"
]
},
"inline": {
"local": [
"d137695d8k.htm"
]
}
},
"keyStandard": 22,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2025": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 23,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2025": 22
},
"report": {
"R1": {
"role": "http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation",
"longName": "100000 - Document - Document and Entity Information",
"shortName": "Document and Entity Information",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "duration_2026-08-21_to_2026-08-21",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d137695d8k.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "duration_2026-08-21_to_2026-08-21",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "d137695d8k.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "AmendmentFlag",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"terseLabel": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CityAreaCode",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"terseLabel": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"terseLabel": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"terseLabel": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentType",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"terseLabel": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityFileNumber",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"terseLabel": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation State Country Code",
"terseLabel": "Entity Incorporation State Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityRegistrantName",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "LocalPhoneNumber",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"terseLabel": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre Commencement Issuer Tender Offer",
"terseLabel": "Pre Commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre Commencement Tender Offer",
"terseLabel": "Pre Commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "Security12bTitle",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Security 12b Title",
"terseLabel": "Security 12b Title",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SecurityExchangeName",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SolicitingMaterial",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"terseLabel": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "TradingSymbol",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"terseLabel": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "WrittenCommunications",
"presentation": [
"http://cytekbio.com//20260821/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"terseLabel": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
}
}
}
ZIP
14
0001193125-26-361705-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001193125-26-361705-xbrl.zip
M4$L#!!0 ( "M0&%T 7=".:P, (P, 1 8W1K8BTR,#(V,#@R,2YX
M
&7:#!7W[!L"%2YI,.I%5,8U\')HP/,RU
M2)1>DMQJ8E
SKD*R0D1/QRG/>8<><<;S#'(DJ6Z(XXP%.SI?+L#X]%H0EPM6!=C[$$$
ME[<[$)X\=V715[(!N9\$0'IT=$0"=6!2;A][T$C_0&IBC]MHNQE&]SATU-A2
M;X^*IZRYJ;6:SRN+YTH79[B@E7 **OEO105?<,P#EZO\ J5]Q/.8PU*]1'M%
M"S0E9;AW\EQY;HN4
DXGJ2)$Q:!W+!X1U$ >;4A;;F\R)"NUO8VQ#S5$_X0^\-3VK=WTHLC
M,!P/WO\C[W]ZL)?_&^/E)UBBY-5KC>G-R)?G1%+.ZA%8'_?/RQKYJMILYXR/
MPV[%P\'T?*
WAY8E
MEPO5/+E'W[M9V\ S7$#8 QG53"N!N[<%*;4J45ON-N5Z!M0";C0NII%?F'$[
M7K\+.D_<>&U9-A0\GBJ>3!P$Q>7:O!9KN?7@2T\&3W>?'%1THGT73"/CHB]Z
M4^E_=K?4^%QW'<2XA1;2]K37?_>XGNV\UW/M., ?OLXNMJ_$;B<22Q^45,6J
M-O!,L
&J2A?!I BX6YXSQ_Y]+_;.P-;$'-W'+P^EFX[\
MSWT;MQ+Z1RISJ,5!3]XQ&0H9RJ\,YG_)DW!F5+!*= %OP W'+N P5?LCUY8]
MC6M>VV2U+4R&/=R\]'N]?JHGCKO^ %!+ P04 " K4!A=(0WGRET& "]
M0P %0 &-T:V(M,C R-C X,C%?;&%B+GAM;,V<;V_;-A#&WP_H=[AY;S:@
MLN-DZUJC:9$YR1 L;8+&W88-0R%+C$V,)@U23NQO/U)_&CFF9"H\37G15I;N
MGKM'^9U*RW+>OE\O&-P1J:C@Q[UA_Z 'A$
4*\%6B994_4@L!A $
M1?QX\AE^S\J-X!-A)%0$#E\-#^"7%67QZ/#@\-6!?MD?EI,D"8T:Q&%"1O!Z
M^C'R#-.A6<$\;(
M!LXI#WE$0P8W1<,OX8)'?3AA##Z9-*6[5$3>D;B?JS+*_QV9OZ:F=WCQ#8 ^
MB5RE^XY[YE3D9V(]E:POY$PW>W T*%)Z#QGKG93[HS1A^.;-FT%ZM!RMJ"U6
MBP\'?WZXO(GF9!$&^N3K'U:4EU%TI-+]ER)*SZ%#@U 985X%15A@=@7#P^!H
MV%^KN/?.%,S/3C@E[%)O0>IA) 4C-87-X;1Z+X]/-DL=3]8)X3')E;]JBRB/
MFDMRFZD:]%))1:+^3-P-8D(-(3^9C
;^GF7*L/?A?8_;P
B#I$4("
BJ@)\L&U1A )
MVZP"Y"4@K0&ZB#? +;9>!KEY_WY(GXIH9>9FHKMW)7D[IR. K8V+W6,^N.[J
M(%%:"(-1]D83O\TRD8Z]XF!X3205\1F/3_7[F:8\/DKN&$R[%5$3A(&J11";
MV:P$Z!I@BJ#AVT+K5HZ=^\=8+'PB,VH6R3SY&"Z
8N]D4SBG^0^ @CSL36P4AK0AY23 UD8;D?_!EF9FGF\,8HG/*R,?58DID
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M8N:#:"S2Q\',5P3DU>VM^\*A3J$CC!U,B7V1/ECO4T7"6Y>!
D_ !:=YS$&U0;MP[ 3CS@2%=IM#496KM7Y:,E1[90T
MLN6YO"'12J^G-L/#Z80FS/D>QVY>5TN;*@/"?MQK66/5PEK4Y.*@U2&5]U_3
MM-+OUHJF0=-^H$YD:+YN>[-93(7S$OQ14D>(VEL7EH,^<%J$D,C,E2&3]J:R
MA4;+2+IVBW/=/%M'<^V6-'FBVY[;\?73:D14QV!<1W?UL*^E106<)[K;Z]MZ
M375L'N/SO;,%D3,]-;]*<9_,]6)D&?*&WV:LD.CT$[YZ6V)OJ/]G?#6R2*SG
M'XP5A2"K!'DII,_X6K1A^9#/U4MYQZ7>,K]W(M]%L]^^H/?\!U!+ P04
M" K4!A= LS"-K<$ !S*@ %0 &-T:V(M,C R-C X,C%?<')E+GAM;-6:
M78_B-A2&[U?:_^"F-ZW4$ (SLS-HF!5E9BK4^1+#ME5O5B8Y@+6.C6PSP+_O
M<< K F$6IMLJYH(/Q^_Q>\YC3&)R^7&1
PG)Q)BI;D71?#ZOI2,FM.0S
M@R%U+9%91,+0]>\./I$_5L.U2!\X4 VD<1;7R:\SQM-6H]XXJ^/'6KPI4D!M
M-))2 RUR'C5.(MN1Q/56\[S5_$ Z]^2&:@-*D '+8%,KITO%QA-#?DI^)KGJ
M6@H!G,.2W#)!1<(H)\_.\"^D)Y(:Z7!.^E:FT:4&]0)I;1V5,_&E99^&UCMY
M_X[@ \LH=-[:#FPQUK58#!6O235&N_5FY$3!IF:Q(YHW
+_34K
MZXT#Q-%?]W?/R00R&B("1)9L#85N4O-5O6GN-%H==/TU:^D\TIU,\MH?D!;9
MV\-^"EVWT#:%<2-LQK6%3H,K.^2JJDIRZ,.(V-=/_=[7,9.E@2]#)O/9E*.O
MGS?BR-"%%#);1K9_="V360;"N->.2&^$86;9$R.ILCR+@.0%;4T4C-I!8KX,
M0Q?->OFQCX$^'Q/(+*?XE= LFW((2+21RU3AO!$F[WV'#04!+ R(%%(7QB;P
M'V1[M:*YGK(R*63OOK,Y*@U);2Q?HA28'?'4OK&E.
*9F5%F<]FBPU*E4*JATT&C7\G@=DJIA4"!M;
M C+3Z$5.K6O*[3$8@5*0WJW2WNLRMXAKIH:\YW?&LYJ-7
+Y=E:]3R7_'']63DB_,[A6^A>!.
M#$\P[OAV+/VY5"_D\R2UH?QO-CW^U+0\@B<
4+3K24
UZ=9S\V6'Y$_T9$%V993.Q/D?6A\+:
M(ZXNL3V&'39_-EF>)6<),TR,[_''6#%K[3!F9
:ZX=17_V4[:RZ6D] _7O69;$\89HB?
(9E9BW%C.&"&'WPJN:NK+K==KXZ3/[LG T7MS57/RVPH#_ZYVQ)5E]"6
M48?'G_T1-\5N%LF$BC$<\U]=N;:ZL,K].F:^[8/<9*#&./=^4W)N)KB^3ZDX
M\GZ3/2&J2_!5VP[D_[ 5
^X
T=:5/C./8[OT*5
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MG0P&Q>=! *,ZY3^^7-RX Q;0(@^5IJ&;C1]KN1":9AE:TXY
\$;'1QY_($J/?/:IX'$5^72$>L0*
MQ^2(#UO8F\GD._<\%MKOT.72*A$):8#O,MXZ"5CHP5]]YM.[!(*A[K(^-,?2
M<.M/E'OD5M7Y4XO<4X%P[U.!#Q] 'IS"<9_ZBAV5)V::F1G?^(
1GOPTD(HE6J9@:H-)0>6DSE:X4* G+)RDG
MV$Y@:)Z5B*5]-'K82LAKN+4">=/7F&%6]L@]_*'/F22&A&RNE6B?_SK)H.F7
M$>JYXT? 0>%ECV @I#ZEFAV/84O?'+>-8?46]$U;LFFS>
.:]^
M95!3^,@I*[Y5I#Z_"ULNX,)D8;+]D7MZT#HH-7AXF.OKL[X^#*B\XV$1O[<(
MC;5(?Y'\;I#\-#4<6M_B@)EV\/%1-H@642OWV!-:B\#\TA,2@$]_<:(A4<+G
M'OFA8OX4CO_V@[-7.9R#6WZRVO+)JL^?+$JGR@U
N2$GEZ>D\T?['R>7OW1(^^K+E_.;F_.KRU?!6%T'
MC+]3-8!X4HMPEYR6VB52K33JS2FXIB9=)I]CD8B>IUEYZ=Q[D726*M!M4D /
MK;Y6G9]F\5]17_,2_I2<6Y:\@62=776_+(X63H4;8["0"U=>$"SL5PLV+)IT
MQ1^BL3'16(M"@\GI=BYO2;=S?=6]?7\#
N)M#L-&OUQ7"^&6
8TH0]0$\B33/S=EKO3]NE)NK:!&T=&\L]VU;95!7ME6YY,$ KP\\
M.AH!25B8MV6UPO%)?!<#D:K.+L$Q/NS:6]FU:GVCHF1SSRZ[XPK7+_0EM+S"
MZ]7!A.)R$OG,A7*Y2
WAB7_T:2_;Y<:8L@X$I]#4Q BT6L8O[_T/^\>T,Z0>2+$9/OSH%)
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MMHM!M!^CVR:0/5.02)"*Q:8 C= )]'NE^%:!? ?[^SO+:G3&$U\(X-
FWTV&H%# T.&V7-/#$F/^>(168>-R& R
M85L>!UPS$](R$,9'2:-D5]J8%=+G/JHG5Z"KFH4>L%X+X'X0^YJ&3,3*'Q$%
M\J_Z(S-#\H+H <5L6I#L_^46SV,8!\0J'*5M?8C,Q2.^A\Z88WJIIG?7QN38
M>VG>L-:\8"89&"<*LQG)5,:RDF
*A!XO+FKHY\:.[7ZX>SUNYYCM'BE9,',BD"Y-5>;6:RA%9
MG#RQ2)3;<.]"@D'JU48BTE/[W+B]O>WLD_99EU1KE1)T?$Z"_"'G+Y?S&[#F
M+G AO/L"AA"LH;\Y(6]\RT(^)A0,;2DU*^%+/893IT6GFCJ-L3),5'JDJK!T
MM&J]4K(CCL/;#ZUY ZVYE@P] ^[)F_HV=/CRJM]_0
R_2O1HKUK?=
M]>I>,N;*NK?V%#(7N-I
PROYAF7]M>]*VDJ(COO@M]
M,PJ@:5NMIPC@NV'/95*T:L27)7[IW9DE0@*Z#Q"-7
BE3$[#N1>5O$]'X:B#,_O,S0IJJO+H?\@OOH @
M'8(L'\(L\H7*>S:S4?ZV$>%YZ&&4S$AO1%RSP0 CWH,",U.2-[6JSQ6!,!
V7-ZNFU8:9/9PT/A,4(UL(W_W#^WB:=J;
MFTK[""OM<9-JQ9"]VBMFZU.KG4C*9E\M?I^9( =GZ76GFY9SJK. ZDL* ]+7
M?C%OM>U+&TLWF\X3Z>9FZ7/>?T(V<1]ZKJ#SF9VK 8BQT4\0XU"8I"A6S/0"
M@B7[8WC)!S=;7_;(/!+(S.6/
^ *W@/EH*&+ZZ_4=;%V
M'3OC=1\>E9ZR.V/>DQE9;9MF&5E>HDLD(_NB%&V58_$+MVB_JQ/V$SNV6UOS
MA9(%,S*)/^7BE1X#KD.\XC_2D<)0$(BV=33(0AO(485L_= T?PY3?*)A/@]U
M?48E^KJ!R?2VEFR+K_<.A:VW.WH%^JE9@'4B%>=POP2!3Y?=Q;[=/CX[):=<
MN;Y0L60ELMA2["V S* /&@Y4PJ6ZYQF.JY#8
)035/SN$.*'T(>NVBC1A032@6M8_0'>([OX4
!LCB5K[$LQR!R B8KRG;H(U,B)<'V4;!W')
=L![7)-FL^2@!3-^LAU+B9V3D[?(]54+%4JISWV!
M"WF59-P"ID#8]#(GXS1I&M\8K%"HB1'G-!YX!9XIFMOCFJD\*7
(V37<7
[*A40)_-';%,'5R"M2=A$'%D.):
M()XR6?:RBDU:TP,4ORL3KG?P]+KZ>BPHTKJ=9@??DF5$S3?P]0%F+QTQ9^Q-
MM6.?/J#88Z-D;%SI%$L0)L7P!H$4"M>G/ 'TL
#P4H(* &4>?$E+U8
M9^CE?AXKE"=
Y=&.NW\%"@=M#RA0OA+A'K S$@2'E&YNGVS7YY<3]
M&R(;U/P$-35.DQ%H$C(:)J.'CM011TA-NZ@(^D@K*+N82P=AQ-1MH R8"
MC@DO7MT_>7IA9=+OH?!.ON]T7A &["8KNVAXIWQ\$ALHVF>00DO(Q])HQ(5D
M*7'BUI I"X@U)(H]14ZK%"S_$Z3JT#G5YVF3;,R"H>B48;#JEIB%W42IU.[X
M]"G8(Y
)
M>HF
=WP8-Z"R&P<^:A2'F+TXM8NR)@%G?@J!4_M*5/,@^[0^IA:./AY
M+DZ
3:>-X^1#NT8:V>5DT(3
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M4
, #71&P$>$HU)>:RD6T6])CG)6%0$H&=F^O]
M"=[OC\L#YM;%G9Q2/7T'1MY7+]Y>R7NGK?P&%6CLQQ[5F^Q1S:T\.__E\N3V
MMV[GYK6[#\WG+EOD;WVU"T\F/K11V*JY^YS-;2_VDT31L[&M/=V;I(D*L+>Y
M+"[.]=B ^OTTWS'A;M(!0G\6AYC8X7# JX&0@)CW74=ITW'9U"&!!D98JT=J
M"^^ 67&8!;7!:P*BD86+4T'#FUUULEJ=]?-NWMC(F&-W6EL:G2Z\&/6IBS56
M>!-WMZQ7@DQ4\GG4VA"LSTPZ
MEE31/-.!E569_,["'D11_^34EI&_7Q7P-V93-C'F<9X;N^1Z4#HM?3#D/1F"
MF:+Y_W_,LEI[P%D? KGT7J(K
U;67/<
M-A)^5Y7^ THY2JJB3MN)+4U4JV-D*RM;CB3'R;YA2,P,+)*@ 7+&DU^_7S?
M8T:'[5A*[<-NI4H>$&ST^?4!;N_5U>NS_=ZK_L'Q_O)2[^KTZJR_W_]C_<6+
MC>W>IO^)]
<;SW2^(F2J1SD(J&&Y
MPL>\K;=ETHYTOEZ:8G>K*/=$^#TP96DROS0T>;GN]%]J=[O]/9293F>[5SI3
M3KQ14W%A,HF3#LY.7[[Y9<42DRO[O
Q'NA2D,2BMWFXW]M\2R+?QL'.
MTP=D(6:=, ^_5G8F3G2>.*%S<30KU?6/WSW?V?YYSXD3.3%6F%Q
?7/1?G[^YBL01'&JX$2TO'52CRI5\/'' ?W[,!Z[8
MV]F.Q,[6SD^T*%9?GIT?]L6;_OO+]Z<7_37!ZM_>\[80A]JX6*L\5BX2IWF\
M(59IP\[6WLWG_ !O=C
J)G&%';BIPD2POE6-9@L '\BSX%)WZ
M+M?D,)>E+*&Y8^U*J^,2CE/9$JKUK#7+<+1CE
9O"*:3FYX_
MK#V_K#V?3AR2]\O:^\/Y,0
;?)XG/F "MTAT"44YBA,EX[$G:YP*
MIWA*&^*]+L>0VQ4*PF*OR<.SB+GH\)T;D4*Q5J;S:AA492-99QD+RJLZ,3%4
MG;-DZF.EP1TVN(YB2/L)2^E*D
K!' !$&0MJBLJV!=T%FO+9Z9X',!
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M;^S.08CX@0)!4B6:DE"KJ,(0 FKF!1 KBT)A9_#8>
Y;NWJ'\#SRT_/S_[88^ I]2Q3->Y]MV%
M*!1JV\^>[/4V\=X^(DV6,%#&1WEGXH2?Z9+.!'>)2O6$$0<
%=U=7^Y^-/#&;QS=%-]
M+2]Q^26@O"\NP(1,)C*/ZY28JT^E&*D\9 #&NSD"I3$(O\&L:\(Q6I)U6"C0
MCOP">6.->;S@%-(_#$W(-T\4KZ7Z+_8&
^W#13U!2^TJ &D[5+P!O*44)")"E72XN= *NT,M K
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M+4
INTM\8,7T'!^ZA-:ST+), KNU:C7F+4UUK(/8T8-/! XI)-']P'
M1*(PSZEL-_E:H_K-X]/?40^%(>KRDN#_>H5PY2Q5\Q8A:%DP""T58&]] "ZO
MUP<*[*A=F4[ES*V@QMHLZ)!7%^+R]#_0P9.5FBX/>7>_>\'_6Q'O3X^O7OVR
MLKVU]4,S]3OJO[GJ7_S/C7F]3T5WU3X1Y>+YQ!0M9)4;"35:0&M1@S7:UGY+
MC9-'Y+&OQ2_V!_3["
^UN;3&;VO=Q.YU3H$."OID!'ET:*\2UW>NEBBLT
MZ3I 4/^3'X+0\"/3CFN@U
G>G\6B7@G1R9EIDH'OS!/_ /
M&<>FRDO_S+5H"57/P2C#]'U0&
Z.8(#UYX?H5N;WO3BY:5[
MW?C>.'VH)OG$6)H2K9\9
?_)DX@(T)@J48EWC_GWM_NWO-\ 7DOHZ3RA-L.[:O A
MW ]TKG6<'"KJ6P?&UN.K&$F%0A8=O[]L<)X1^-$!4DE'>YV*I5U=7@(CL 9B
M@4N(H>P42'?884.
JAK'I4O4X8W#@"H !FX*6!L
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M7*V?CFH6;@O"E
Y]TJH;L1+EF"& "'^B82U8=)T>E?H_'S
M;E'E_M]6NVN<3W4>EV1-<>S]C-"8BA8.2ZJJ8DG@B=6*BL5@B:BK*+)#F#]Z
M-8'73LTV=Z
0_:8O<]T;\ANC4_USZ>.F"O%T!\8)%
M&O3'HS;@V,'?*,P2:M2!NSM==[F5X]EJ %B^R;J+/JN+L1S)DB
DO@:;J#'X##CY".+&LD:+%J6ZUWJU
MC3BJ.0YT_@$*Y"L>RR&!:,Y'AC;[J_R9,*A<1P&#D9=IDD=)IDWJ,=T ,A>;
M+4PV.)1J.= IET%[/%K"VDB9PM :ZHY(*" ,6IJ8Y:!65I5<*'M> Y)XLM[L
M5/97[*
TBT!Y2O*4.HBLP>MA:LC^!
ZA3/Y6I=>40%GT;U:JMMSFLL1[I1B!,>!BE5+):2(
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M)M6/?K<&GSNMA\__I-N]1FTH7BM%
FQ9X4M9QFK]5_>BI.M,M^1R&/S\^$\L\O_;X[]02P$"% ,4 " K4!A=
M %W0CFL# ",# $0 @ $ 8W1K8BTR,#(V,#@R,2YX
M
&UL4$L! A0#% @ *U 870+,PC:W
M!
8A !D,3,W-CDU9&5X.3DQ+FAT;5!+!08 !0 %
+ $ ! "O,0 !
end
XML
15
d137695d8k_htm.xml
IDEA: XBRL DOCUMENT
0001831915
2026-08-21
2026-08-21
false
0001831915
8-K
2026-08-21
Cytek Biosciences, Inc.
DE
001-40632
47-2547526
47215 Lakeview Boulevard
Fremont
CA
94538
(877)
922-9835
false
false
false
false
Common Stock, par value $0.001 per share
CTKB
NASDAQ
false